Likarda Chooses Science Exchange as the Primary Online Channel to Offer 3D Compound Screening and Assay Development Services to Scientists

February 28, 2018 | Posted by Team in News |

Likarda Partners With Science Exchange

PALO ALTO, CA, February 28, 2018 – Science Exchange, the world’s leading platform for outsourced research and development (R&D) services, announced a partnership with Likarda to offer online access to its innovative 3D compound screening and assay development services to scientists around the globe.

Likarda is a Kansas City-based contract research organization (CRO) and a leading provider of drug discovery and development services, primarily using 3D cell-based assaying technologies and microencapsulation. The company’s mission is to combine comprehensive early-phase discovery research with consultative and analytical services so that those in the drug discovery process can move forward confidently, efficiently, and affordably.

“We focus on bringing to market disruptive technologies that improve healthcare outcomes and lower costs for pets and people alike. To illustrate, our proprietary three-dimensional cell culture system serves as a predictive model to demonstrate how test drug compounds work in the human body. Partnering with Science Exchange gives its global client base the fastest path to our novel technologies and services,” stated Karthik Ramachandran, Ph.D., Likarda’s vice president and co-founder.

“We are excited to team up with Likarda to make its drug screening and assay development services accessible to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists can securely and readily access the services they need to aid their discoveries.  Likarda met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of 3D cell-based assaying technologies and microencapsulation.”

About Likarda

Founded in 2012, Likarda LLC is a world-class, cutting-edge biotech research laboratory for science entrepreneurs, pharmaceutical and nutraceutical companies, animal health, and contract research organizations (CRO). We focus on bringing to market disruptive technologies that improve health-care outcomes and lower costs for pets and people alike. Follow the CRO on Twitter @likardallc.

 

Interested in trying out Likarda’s technologies for your project?

Request a quote from the Likarda team

Tech Q&A with Likarda, LLC

February 5, 2018 | Posted by Team in Provider Spotlight |


Guru Singh, Director of Scientific Content, recently spoke with Dr. Lisa Stehno-Bittel, President and Founder of Likarda LLC, an exciting biotech service company on the Science Exchange network.


GS: Nice to meet you, Lisa! Why do clients come to Likarda?

LSB: Likarda is the company you come to when your scientific questions require complex solutions. Our scientists work to create and validate novel assays on a number of different projects, in a timely and efficient manner.

GS: What capabilities does Likarda have that differentiate the company from other service providers and cell-based assay experts?

LSB: We have a strong portfolio of platform technologies that allow us to conduct assays that just aren’t available at other companies. First of all, we have a series of patents around generating, in a high throughput manner, 3D spheroids for drug screening, efficacy testing, toxicity testing, etc. Our Likarda CC Microplate is made using standard plate formats, but in each well of a 384-well plate are 150 different single microwells, in each of which we can grow a different spheroid. That way, we can reduce the number of replicates, saving time and money for the client.

GS: There are many different plate-based models on the market — organoplates, microfluidic chips, etc. — How do Likarda’s plates compare?

LSB: The difference is that Likarda’s plates are really made for a high throughput format and are ideal for complex experiments, for example, when you need to work with multi-cell-type 3D cultures, in an as natural environment as possible. Most of the time, we don’t use any sort of gel or matrix for the 3D cultures — the plates are low-adherence, so the cells stick to each other and not to the plate. This makes the plates easy to work with. We do have a patented hydrogel technology which allows us to make microencapsulated cells using biocompatible materials. We are the first to use these materials for microencapsulation. Microplates and hydrogel — these two technologies really set us apart.

GS: Very cool. How would you describe Likarda’s team?

LSB: All of our scientists have advanced Masters’ degrees in biology or physiology or PhD’s in physiology or bioengineering. We’re a relatively small team, so everyone is involved and gives input into these complex studies that we typically do.

GS: Your clients seem very diverse!

LSB: Yes! Our clients are in the pharmaceutical and nutraceutical industries, as well as food supplements and hygiene. We do work for multinational companies as well as smaller startups.

GS: How has Likarda grown over the years? What lies in the future?

LSB: We started Likarda 5 years ago with money from family and friends. Within 17 months, we were revenue-positive! We’re revenue-driven, and we’re working also on our own products — microplates, hydrogel, regenerative medicine therapies we’re getting ready to take to market.

GS: Can you talk about Likarda’s certifications?

LSB: We’re a woman-owned company, we have the capability to run GLP studies, and we can maintain GMP status for drug development projects, we have continual environmental monitoring.

GS: So, I take it, Likarda has had a successful experience being part of the Science Exchange network.

LSB: Definitely — Science Exchange has been wonderful to work with! With Science Exchange, you have a sourcing agent assigned to you from the very start. That person really does a good job of figuring out what the client needs, and matching them to the right CRO for their research.

Connect with the Likarda team to discuss your project today by visiting www.scienceexchange.com/labs/likarda-llc.

New on Science Exchange: VR Tech, Cancer Genetics, Stem Cell-based Organoids

October 26, 2017 | Posted by Team in Innovation Highlight, New Innovations |

Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange | www.scienceexchange.com

Nanome Virtual Reality

Virtual Reality Software: Explore biology at nanoscale

From “Fantastic Voyage” (1966) to “A Wind in the Door” (1973), fiction has adored the idea of exploring the body at cellular and molecular levels. Now, virtual reality (VR) software, combined with the computational power afforded by blockchain technology, makes such journeys possible.

For your next computer-aided drug discovery/development (CADD) project, especially if you are collaborating with researchers across multiple sites, try molecular visualization using VR technology — now available from Nanome through Science Exchange.

Visit the Nanome storefront to connect with their team!

 

Cancer Genetics: Connect patients to discoveries

It’s a great day for precision medicine, with the unveiling of the first global directory of patient-derived xenografts (PDX).

Despite the attention given to precision medicine, however, less than 5% of cancer patients are participating in clinical trials. In the discovery phases of R&D, obtaining biospecimens of specific genotypes is also a continuing challenge.

Oncologists on Science Exchange can now accelerate their research with Cancer Genetics, Inc., a global CRO with a history of thought leadership in precision medicine.

Start a project today with Cancer Genetics, Inc.

 

Stem Cell-based 3D Organoids: Predict Preclinical Efficacy and Toxicity

3Dnamics Organoid Hippocampus

Organoids, particularly brain organoids, have enabled breakthrough research in Alzheimer’s disease, glioblastoma, and even ZIKA virus-induced microcephaly. By using pluripotent stem cells as a source of the multiple cell types present in an organoid, preclinical researchers can recapitulate in vivo-like tissue architecture and cellular heterogeneity.

Many of these discoveries were made by the founders of 3Dnamics, a new service provider on the Science Exchange network. The 3Dnamics team was built by stem cell pioneers and neuroscientists at Johns Hopkins University School of Medicine. If you are in the process of developing a model system for your preclinical or discovery-phase research, take advantage of 3Dnamics’ expertise.

Visit the 3Dnamics storefront

 

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com